HMS LINCS ID,SMILES (temporary),Name,Synonyms,Search-index-only names,Class,Nominal target / Pathway,Binding mode,Lipinski rule violations,Molecular weight,Lipophilicity (logP),Chiral?
10001-101,CC[C@H](CO)NC1=NC2=C(C(=N1)NCC3=CC=CC=C3)N=CN2C(C)C,Seliciclib,(R)-Roscovitine,CYC202,Phase 2,,,,300-400,,
10004-101,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,,,Phase 1,,,,300-400,,
10006-101,C1C[C@H](CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N,AZD7762,,,Phase 1,,,,300-400,,
10007-101,C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOC[C@@H]5C,AZD8055,,,Preclinical,,,,400-500,,
10008-101,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,Sorafenib,Nexavar,BAY-439006,Approved,,,,400-500,,
10009-101,COC1=C(C=C2C(=C1)C(=NC=N2)N3C(=NC(=N3)C4=CC=CC=N4)N)OC,CP466722,,,Preclinical,,,,300-400,,
10010-101,CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)C=CCNC(=O)COC)C,CP724714,,,Preclinical,,,,400-500,,
10011-101,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O,Alvocidib,Flavopiridol,HMR-1275;L86-8275,Phase 2,,,,400-500,,
10014-101,COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=O)N)OCC4=CC=CC=C4C(F)(F)F)OC,GW843682X,,GW843682,Preclinical,,,,400-500,,
10015-101,CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=NC=C(C=C4)C(=O)NC,HG-5-113-01,,,Preclinical,,,,400-500,,
10016-101,CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC(=C2Cl)N)NC3=C(C=C(C=C3)N4CCC(CC4)C(=O)N)OC,HG-5-88-01,,,Preclinical,,,,> 500,,
10017-101,CC1=CC=C(C(NC2=CC=C(CN3CCN(CC)CC3)C(C(F)(F)F)=C2)=O)C=C1/C=C/C4=C(OC)C5=C(NC=C5)N=C4,HG-6-64-01,,KIN001-206,Preclinical,,,,> 500,,
10018-101,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,Neratinib,,HKI-272,Phase 3,,,,> 500,,
10019-101,COC1=CC(=CC(=C1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F)OC,JW-7-24-1,,,Preclinical,,,,> 500,,
10020-101,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C,Dasatinib,Sprycel,BMS-354825,Approved,,,,400-500,,
10021-101,CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)SC4=CC=C(C=C4)NC(=O)C5CC5,Tozasertib,,VX-680;MK-0457,Phase 1,,,,400-500,,
10023-103,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Imatinib,Gleevec;Glivec,CGP-57148B;STI-571,Approved,,,,400-500,,
10024-101,CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC,NVP-TAE684,,,Preclinical,,,,> 500,,
10025-101,C1=CC(=CC(=C1)Cl)NC2=NC=CC(=N2)C3=CC(=NC=C3)NCCCO,CGP60474,,MLS000911536;SMR000463552,Preclinical,,,,300-400,,
10026-101,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD173074,,,Preclinical,,,,> 500,,
10027-101,C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,Crizotinib,Xalkori,PF02341066,Approved,,,,400-500,,
10028-102,CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN,BMS345541,,,Preclinical,,,,< 300,,
10031-101,C1=CC2=C(C(=C3C4=C(C=C(C=C4)Br)NC3=O)N=C2C=C1)NO,KIN001-043,,,Preclinical,,,,300-400,,
10032-101,CN1CCN(CC1)CCOC2=CC(=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6,Saracatinib,,AZD0530,Phase 2,,,,> 500,,
10035-101,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=NC6=CC7=C(C=C6N=C5C8=CC=CC=C8)N=CN7,Sigma A6730,,KIN001-102;AKT inhibitor VIII;Akt1/2 kinase inhibitor,Preclinical,,,,> 500,,
10039-101,,WH-4-025,,,,,,,,,
10040-101,CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C,R406,,,Preclinical,,,,400-500,,
10041-101,CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C,BI-2536,,NPK33-1-98-1,Preclinical,,,,> 500,,
10045-101,CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N,A443654,,,Preclinical,,,,300-400,,
10046-101,CN(C)CCOC1=CC=C(C=C1)C2=NC(=C3C=CC4=C(CCC4=C3)N=O)C(=C5C=CNC=C5)N2,SB590885,,,Preclinical,,,,400-500,,
10047-101,CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6,GDC-0941,,,Phase 2,,,,> 500,,
10048-101,C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl,PD184352,,CI-1040,Phase 2,,,,400-500,,
10049-101,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)Cl)F,PLX-4720,,,Preclinical,,,,400-500,,
10051-104,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,Lapatinib,Tykerb,GW-572016,Approved,,,,> 500,,
10052-101,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,Sirolimus,Rapamycin,,Approved,,,,> 500,,
10053-101,C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5,ZSTK474,,,Phase 1,,,,400-500,,
10055-101,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,,,Preclinical,,,,400-500,,
10056-101,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,Selumetinib,,AZD6244;ARRY-142886,Phase 3,,,,400-500,,
10057-102,C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N,MK2206,,,Phase 2,,,,400-500,,
10059-101,CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4,AZD-6482,,KIN001-193,Phase 1,,,,400-500,,
10061-101,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56,NU7441,,KU 57788,Preclinical,,,,400-500,,
10063-102,COC1=CC=CC2=CC(=C3C4=C(N=CNN4C(=N3)C5CCC(CC5)C(=O)O)N)N=C21,OSI-027,,,Phase 1,,,,400-500,,
10064-101,CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=NN3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7,WYE-125132,,,Preclinical,,,,> 500,,
10067-101,CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO,Barasertib,,AZD1152-HQPA,Phase 3,,,,> 500,,
10068-101,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F,Vemurafenib,Zelboraf,PLX4032;RG7204;R7204;RO5185426,Approved,,,,400-500,,
10069-101,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7,Enzastaurin,,LY317615,Phase 3,,,,> 500,,
10071-101,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,Palbociclib,Ibrance,PD0332991,Approved,,,,400-500,,
10072-101,CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C,PF562271,,KIN001-205,Preclinical,,,,> 500,,
10073-101,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,,,Phase 1,,,,300-400,,
10075-101,CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CNN=C5)NC(=O)C=C,QL-X-138,,,Preclinical,,,,400-500,,
10077-101,CN1C=C(C=N1)C2=CC3=C4C(=CN=C3C=C2)C=CC(=O)N4C5=CC6=C(CCN6C(=O)C=C)C=C5,QL-XII-47,,,Preclinical,,,,400-500,,
10079-101,CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F,Torin1,,,Preclinical,,,,> 500,,
10080-101,C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F,Torin2,,,Preclinical,,,,400-500,,
10082-101,O=C(NC1=C(Cl)C(OC)=CC(OC)=C1Cl)N(CC2=CC=C(NC(C=C)=O)C=C2)C3=CC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=N3,WZ-4-145,,,Preclinical,,,,> 500,,
10084-101,CC(C)N1C=NC2=C1N=C(N=C2NC3=CC(=CC=C3)NC(=O)C=C)NC4CCC(CC4)N(C)C,WZ3105,,,Preclinical,,,,400-500,,
10086-101,CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C)OC,XMD11-50,,LRRK2-in-1,Preclinical,,,,> 500,,
10087-101,O=C1CCN(C2CCCC2)C3=NC(NC4=CC=C(C(NC5CCN(C)CC5)=O)C=C4OC)=NC=C3N1C(C)C,XMD11-85h,,,Preclinical,,,,> 500,,
10091-101,O=C1C2=C(C=CC=C2)N(C)C3=NC(NC4=CC(NC(/C=C/CN(C)C)=O)=CC=C4)=NC=C3N1C,XMD16-144,,,Preclinical,,,,400-500,,
10097-101,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,Erlotinib,Tarceva,OSI-774,Approved,,,,300-400,,
10098-101,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,Gefitinib,Iressa,ZD1839,Approved,,,,400-500,,
10099-101,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5,Nilotinib,Tasigna,AMN-107,Approved,,,,> 500,,
10100-101,C1COCCN1C2=CC(=CC(=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5C=NC(=N5)N6CCOCC6)F,JNK-9L,,KIN001-204,Preclinical,,,,> 500,,
10101-101,C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O,PD0325901,,PD-325901,Phase 2,,,,400-500,,
10108-101,C[C@H]1C[C@@H]([C@@H]([C@H](C=C([C@@H]([C@H](C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)C)OC)OC(=O)N)C)C)O)OC,Geldanamycin,,IPI-493,Phase 1,,,,> 500,,
10109-101,C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N,YM 201636,,Kin001-170,Preclinical,,,,400-500,,
10111-101,C1=CC(=CC(=C1)N)C2=CC3=C(N2)N=CN=C3OC4=CC=CC(=C4)O,TWS119,,,Preclinical,,,,300-400,,
10112-101,CN1C=C(C=N1)C2=NC3=C4C2=CNNC(=O)C4=CC(=C3)NC(=O)[C@@H](C5CCCCC5)N,PF477736,,,Preclinical,,,,400-500,,
10115-102,C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3,LDN-193189,,DM 3189,Preclinical,,,,400-500,,
10116-101,CN(C1=CC=CC=C1CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C,PF431396,,,Preclinical,,,,> 500,,
10117-101,CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CCC4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O,Celastrol,,,Preclinical,,,,400-500,,
10119-101,CC1=C(NC(=C1C(=O)N2CCN(CC2)C)C)C=C3C4=C(C=CC(=C4)S(=O)(=O)N(C)C5=CC(=CC=C5)Cl)NC3=O,SU11274,,PKI-SU11274,Preclinical,,,,> 500,,
10120-102,C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,Canertinib,,CI-1033;PD-183805,Phase 2,,Covalent,,400-500,,
10122-101,C1CN(C1)CC2CC(C2)N3C=C(C4=C3N=CN=C4N)C5=CC(=CC=C5)OCC6=CC=CC=C6,NVP-AEW541,,AEW541,Preclinical,,,,400-500,,
10125-101,CC1=C(NC(=C1C(=O)N2CCC[C@@H]2CN3CCCC3)C)C=C4C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O,PHA-665752,,,Preclinical,,,,> 500,,
10126-101,C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O,PI103,,,Preclinical,,,,300-400,,
10127-101,CN1CCN(CC1)C2=CC3=C(C=C2)NC(=C4C(=C5C(=NC4=O)C=CC=C5F)N)N3,Dovitinib,,TKI-258,Phase 3,,,,300-400,,
10128-101,CCN1C2=C(C(=NC=C2OCC3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N,GSK 690693,,,Preclinical,,,,400-500,,
10132-101,CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3,SNS-032,,BMS-387032,Phase 1,,,,300-400,,
10133-101,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4,Afatinib,Gilotrif,BIBW-2992,Approved,,,,400-500,,
10134-101,CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F,GSK1904529A,,,Preclinical,,,,> 500,,
10135-101,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,Linsitinib,,OSI-906;ASP7487,Phase 3,,,,400-500,,
10138-105,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,Ruxolitinib,Jakafi;Jakavi,INCB018424;INC424,Approved,,,,300-400,,
10140-101,C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N,Momelotinib,,GS-0387;CYT387,Phase 3,,,,400-500,,
10141-101,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4,TG 101348,,,Preclinical,,,,> 500,,
10142-101,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5,Trametinib,Mekinist,GSK-1120212;GSK-1120212B;JTP-74057,Approved,,,,> 500,,
10146-101,# NEEDS CORRECTION,GSK2126458,,,Phase 1,,,,> 500,,
10147-101,C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,Buparlisib,,BKM120;NVP-BKM120,Phase 2,,,,400-500,,
10148-101,CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC=CC5=NSN=C54,XL147,,SAR245408,Phase 2,,,,400-500,,
10149-102,C[C@H](C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2)N,Y39983,,,Preclinical,,,,< 300,,
10151-101,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5,Nintedanib,Vargatef;Ofev,BIBF-1120,Approved,,,,> 500,,
10157-101,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,Foretinib,,XL880;GSK1363089,,,,,> 500,,
10158-101,CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(C=C3)S(=O)(=O)C,AZD 5438,,KIN001-239,,,,,300-400,,
10159-101,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)C=CCN(C)C,Pelitinib,,EKB-569,,,,,400-500,,
10161-101,CCNC(=O)C1=C(C(=C2C=C(C(=CC2=O)O)C(C)C)ON1)C3=CC=C(C=C3)CN4CCOCC4,NVP-AUY922,,,,,,,400-500,,
10164-101,CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO,AZD8330,,ARRY-424704;ARRY-704,,,,,400-500,,
10171-101,CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3)N4CCOCC4,TGX221,,,,,,,300-400,,
10172-101,C1=CC2=NC=CC(=C2C=C1C=C3C(=O)NC(=O)S3)C4=CC=NC=C4,GSK1059615,,,,,,,300-400,,
10177-101,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,Brivanib,,BMS-540215,,,,,300-400,,
10180-101,CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N,CHIR-99021,,CT99021;KIN001-157,,,,,400-500,,
10182-101,CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N,Linifanib,,ABT-869;AL-39324,,,,,300-400,,
10190-101,CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO,PIK-93,,,,,,,300-400,,
10232-101,CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5,BEZ235,,NVP-BEZ235,,,,,400-500,,
10233-101,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,Alpelisib,BYL719,,,,,,400-500,,
10234-101,CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)C(C)O,GDC-0980,,RG7422,,,,,400-500,,
10479-102,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,Mitoxantrone,Novantrone,CL-232325;DHAQ,,,,,400-500,,
10480-101,C[C@@H]1C[C@@H]2[C@H](O2)/C=C\C=C\C(=O)CC3=C(C(=CC(=C3Cl)O)O)C(=O)O1,Radicicol,Monorden,,,,,,300-400,,
10481-101,CC1=C(C(=O)O[C@H](C1)[C@@H](C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3C[C@@H]5[C@]6([C@@]4(C(=O)C=C[C@@H]6O)C)O5)C)CO,Withaferin A,,NSC-273757;NSC-101088,,,,,400-500,,